Medicus Pharma enters $15M equity purchase agreement with Yorkville; plans TSXV delisting

Medicus Pharma Ltd.

Standby Equity Purchase Agreement with Yorkville for up to $15M over 36 months; shares sold at 97% of market price.
Proceeds to fund Phase 2 BCC trial, expand to pivotal trial and other non-melanoma skin diseases.
Yorkville received $25k structuring fee and 105,840 commitment shares.
Board approved voluntary delisting from TSXV; shares continue on Nasdaq (MDCX).
Drawdowns require effective SEC registration statement; 19.99% cap and 4.99% beneficial ownership limit apply.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.